Six months after GlaxoSmithKline paid $250 million for a stake in Vir Biotechnology and a seat at the table developing antibodies against Covid-19, it has a Phase III drug in its hands.
The partners said the independent data monitoring committee has given the green light to start the final stage of clinical testing after reviewing unblinded safety results, expanding the COMET-ICE study to more sites in North America, South America and Europe.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,